Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fighting cancer wasting: can diet and exercise make olanzapine work better?

NCT ID NCT07722806

Symptom relief Sponsor: Kantonsspital Winterthur KSW Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This trial tests whether adding a structured nutrition and exercise program to the standard appetite-stimulating drug olanzapine can improve quality of life in people with advanced solid tumors who have poor appetite. Participants are randomly assigned to receive olanzapine alone or olanzapine plus personalized dietary advice, exercise sessions, and a protein supplement. The study tracks quality of life, fatigue, and nutritional status over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olanzapine plus a standardized nutrition and exercise program
What this could lead to
If it works, this could point toward a better way to manage appetite loss and malnutrition in advanced cancer, potentially improving quality of life.
What could go wrong
This is a mid-stage trial with 130 participants, so results may not apply to all cancer patients. The added program requires time and effort, and olanzapine can cause side effects like drowsiness or weight gain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Metastatic or locally advanced solid tumors, excluding lymphoma, not eligible for curative treatment * VAS score ≤70 for appetite, as defined for anorexia in oncology patients (olanzapine is prescribed according to clinical guidelines as part of standard care) * WHO-PS of ≤3 * Ability to participate in physical exercise, as judged by the treating oncologist * Anticipated life expectancy of at least six months * Willingness to provide written informed consent Exclusion Criteria: * Pregnancy or breastfeeding * Parkinson's disease, known risk for narrow-angle glaucoma, or any other contraindication to olanzapine, as judged by the treating oncologist * Alcohol consumption \>2 units/d * Use of Olanzapine for any indication for more than four days per month * Current use of any antipsychotic or antidepressant medication * Recent use of systemic corticosteroids (prednisolone ≥10 mg/d or equivalent) for more than seven days within the past four weeks * Presence of ascites at time of enrolment * Concurrent radiotherapy to the esophagus * Intake of products with added high-dose BCAA (branched-chain amino acids, total ≥3 g/d) within the past month * Tube feeding and/or parenteral nutrition within the previous month (excluding ONS (oral nutritional supplements) * History of ileus within the past month * Allergy to milk protein * Inability to comprehend trial information due to language barriers, cognitive or psychological limitations, or disease-related factors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer, advanced solid tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Malnutrition metastatic malignant neoplasm metastatic neoplasm Motor Activity neoplasm nutritional deficiency disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer, advanced solid tumors Malnutrition

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.